European Notebook: Salmonson Stays At CHMP Helm; Sandoz, AstraZeneca Build New Biologics Facilities
CHMP Chairman Tomas Salmonson re-elected for three-year term; Sandoz and AstraZeneca develop manufacturing facilities in Austria and the US respectively for biosimilars and biologics, among investments suggesting European pharmas' more confident outlook; more in this month's column
You may also be interested in...
French Industry Rages Over €1.7bn Drug Savings Plan
Measure includes €550bn in drug price cuts.
When Can You Ban Parallel Trade?
European commissioner's statements supporting countries' right to limit drug exports appears counter to EC actions against some who do.
Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany
The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.